Guo Guangchang, is an Executive Director and Chairman of the Company and the founder of the Group. As of 31?December 2024, he has also been a director of both Fosun Holdings and Fosun International Holdings (the direct and indirect controlling shareholders of the Company, respectively), honorary chairman of The Zhejiang Chamber of Commerce, Shanghai, etc.. Mr. Guo was honored the “Lifetime Achievement Award” by the 8th World Chinese Economic Summit, the “Lifetime Achievement Award” at the 16th CNBC Asia Business Leaders Award Ceremony, and the “50 Most Influential Business Leaders in China 2023” by Fortune China etc.. Mr. Guo received a bachelor’s degree in philosophy in 1989 and a master’s degree in business administration in 1999, both from Fudan University.

Wang Qunbin, is an Executive Director and Co-Chairman of the Company, and the founder of the Group. Mr. Wang was a non-executive director of Fosun Pharma (listed on the Hong Kong Stock Exchange and the SSE) and Sinopharm (listed on the Hong Kong Stock Exchange). Mr. Wang was awarded “Asia Pacific Outstanding Entrepreneur Awards” by Enterprise Asia and “Best Asian Corporate Director” at the Asian Excellence Recognition Awards by Corporate Governance Asia, etc., and was named one of “China’s 50 Top- performing Corporate Leaders” by Harvard Business Review. Mr.Wang received a bachelor’s degree in genetic engineering from Fudan University in 1991.

Chen Qiyu, is an Executive Director and Co-CEO of the Company. Mr. Chen joined the Group in 1994 and as of 31?December 2024, he has also been a non-executive director of Fosun Pharma (listed on the Hong Kong Stock Exchange and the SSE) and Shanghai Henlius (listed on the Hong Kong Stock Exchange), a non-executive director and vice chairman of Sinopharm (listed on the Hong Kong Stock Exchange) and various companies within the Group. Mr. Chen was a director of Sanyuan Foods (listed on the SSE), a non-executive director of Gland Pharma (listed on the BSE Limited and National Stock Exchange of India Limited) and a co-chairman of New Frontier Health Corporation (delisted from the NYSE in January 2022). As of 31?December 2024, Mr. Chen has been the chairman of China Medical Pharmaceutical Material Association, a vice chairman of China Pharmaceutical Innovation and Research Development Association, the honorary chairman and chief supervisor of Shanghai Biopharmaceutics Industry Association, a member of the 14th Shanghai Standing Committee of the Chinese People’s Political Consultative Conference, etc.. Mr. Chen was awarded “Asia’s Best CEO” by Corporate Governance Asia, etc.. Mr. Chen received a bachelor’s degree in genetics from Fudan University in 1993 and an EMBA degree from China Europe International Business School in 2005.

Xu Xiaoliang, is an Executive Director and Co-CEO of the Company. Mr. Xu joined the Group in 1998, and as of 31?December 2024, he has also been a non-executive director of Fosun Pharma (listed on the Hong Kong Stock Exchange and the SSE), an executive director and chairman of FTG (delisted from the Hong Kong Stock Exchange in March 2025), a director of Yuyuan (listed on the SSE), Shanghai Foyo Culture & Entertainment Co., Ltd. (delisted from the NEEQ in April 2021, “Shanghai Foyo”) and various companies within the Group. Mr. Xu was a non-independent director of Hainan Mining (listed on the SSE), a non-executive director and vice chairman of Zhaojin Mining Industry Co., Ltd. (listed on the Hong Kong Stock Exchange with stock code 01818, “Zhaojin Mining”), and a director of Shanghai Resource Property Consulting Co., Ltd. (delisted from the NEEQ in December 2020, “Resource Property”). As of 31?December 2024, Mr. Xu has been a deputy to the 16th Shanghai Municipal People’s Congress and the chairman of Shanghai International Fashion Federation. Mr. Xu was awarded “Asia’s Best CEO” by Corporate Governance Asia, the “Shanghai 4 May Youth Medal” and “Shanghai Top Ten Youth Business People” etc.. Mr. Xu received a master’s degree in business administration from the East China Normal University in 2002 and received an EMBA degree from Fudan University in 2019.

Gong Ping, is an Executive Director, Executive President and CFO of the Company. Mr. Gong joined the Group in 2011 and as of 31?December 2024, he has also been directors of various companies within the Group. He used to serve as a senior assistant to president of the Group, the general manager of Corporate Development Department and the CEO of Fosun Hive. He was the chairman of PAREF (listed on the Euronext Paris), a non-executive director of Fosun Pharma (listed on the Hong Kong Stock Exchange and the SSE), and a director of Shanghai Bailian Group Co., Ltd. (listed on the SSE with stock code 600827, “Shanghai Bailian”), Yuyuan (listed on the SSE) and Resource Property (delisted from the NEEQ in December 2020). Prior to joining the Group, Mr. Gong worked at Pudong branch and the headquarters of Bank of Shanghai as well as the PRC headquarters of Standard Chartered Bank. Mr. Gong also served as a global strategist at the headquarters of Samsung Group in Korea, carrying out special assignments across various sectors including financial services, technology and real estate worldwide. As of 31?December 2024, Mr. Gong has been the Honorary Vice President of Shanghai Young Entrepreneurs‘ Association and a council member of Shanghai Association for Youth Entrepreneurship and Employment. Mr. Gong graduated from Fudan University in 1998 with a bachelor’s degree in international finance, and then obtained his master’s degree in finance from Fudan University in 2005. Mr. Gong also received his master’s degree in business administration from International Institute for Management Development (IMD) in Lausanne, Switzerland in 2008.

Huang Zhen, is an Executive Director of the Company. Mr. Huang joined the Group in 2017 and as of 31?December 2024, he has also been the chairman of Yuyuan (listed on the SSE), Lanvin Group (listed on the NYSE) and a vice- chairman of Sanyuan Foods (listed on the SSE), the director of Shede Spirits (listed on the SSE), Resource Property (delisted from NEEQ in December 2020), FTG (delisted from the Hong Kong Stock Exchange in March 2025) and various companies within the Group. Mr. Huang was a director of Shanghai Bailian (listed on the SSE), a non-executive director of Zhaojin Mining (listed on the Hong Kong Stock Exchange) and a director of Jinhui Liquor Co., Ltd. (listed on the SSE with stock code 603919). Before joining the Group, Mr. Huang was the deputy general manager of Shanghai Jahwa United Co., Ltd., and the general manager of Shanghai Herborist Cosmetics Co., Ltd., etc.. As of 31?December 2024, Mr. Huang has been a member of the 14th Shanghai Standing Committee of the Chinese People’s Political Consultative Conference, a member of the 3rd Shanghai Huangpu District Standing Committee of the Chinese People’s Political Consultative Conference, the chairman of Shanghai Huangpu District Federation of Industry and Commerce, the president of Shanghai Huangpu District Chamber of Commerce, the vice chairman of China Gold Association and Gems & Jewelry Trade Association of China, etc.. Mr. Huang was awarded “Top Ten Economic Figures in China’s Circulation Industry” and “National Outstanding Commercial Entrepreneur”, etc.. Mr. Huang received a bachelor’s degree in economics from Shanghai University of Finance and Economics in 1994 and an MBA degree from Webster University (USA) in 1998.

Pan Donghui, is an Executive Director, Executive President and Chief Human Resources Officer (CHO) of the Company. Mr. Pan was appointed as the Executive Director of the Company in March 2023. Mr. Pan joined the Group in 1994 and as of 31?December 2024, he has also been a non-executive director of Fosun Pharma (listed on the Hong Kong Stock Exchange and the SSE) and FTG (delisted from the Hong Kong Stock Exchange in March 2025) and a director of Shanghai Foyo (delisted from NEEQ in April 2021). Mr. Pan also served as a director of Shanghai Ganglian E-Commerce Holdings Co., Ltd. (listed on the Shenzhen Stock Exchange with stock code 300226). Mr. Pan obtained a bachelor’s degree in engineering from Shanghai Jiaotong University in China in 1991, and a master’s degree in business administration from the University of Southern California in the United States in 2009.

Li Fuhua, has been a Non-Executive Director of the Company since February 2023. As of 31?December 2024, Mr. Li has also been the financial director, the head of finance and the general manager of the planning and finance department of AEON Life Insurance Co., Ltd. (“AEON Life Insurance”), the head of finance of AEON Insurance Asset Management Co., Ltd., a director of Shanghai Zhuli (a subsidiary of the Company) and an executive director of Wangjin Holdings (Dalian) Co., Ltd.. From 1993 to 1997, Mr. Li served as the accounting supervisor of the financial department of Jinan silk factory of Shandong Provincial Silk Corporation. From 1997 to 2000, he served as the financial supervisor and financial manager of the financial department of China Ping An Life Insurance Co., Ltd. (“Ping An Life Insurance”) Jinan Branch. From 2000 to 2002, he served as the director of the financial department and the project manager of financial enterprise resource planning (ERP) of Ping An Life Insurance. From 2002 to 2004, he was the director of the financial management office of the financial planning department of Ping An Insurance (Group) Company of China, Ltd. (listed on the Hong Kong Stock Exchange with stock code 02318 and the SSE with stock code 601318). From 2004 to 2008, he served as the assistant general manager of the financial department of Taikang Life Insurance Co., Ltd. (“Taikang Life Insurance”). From 2009 to 2013, he served as the deputy general manager of the financial department of Taikang Life Insurance. From 2013 to 2017, he served as the general manager of the accounting department of AEON Life Insurance. Mr. Li graduated from Shandong College of Finance (currently known as Shandong University of Finance and Economics) with a bachelor’s degree in accountancy in 1998. Mr. Li holds certificates of qualification of Senior International Finance Manager and International Certified Management Accountant.

Mr. Luo Yuanli, formerly named Luo Yufeng, has been a non-executive director of the company since June 2025. Mr. Luo has also been the head of the Board Office and general manager of the Administrative Office of Zhongrong Life Insurance Co., Ltd. Mr. Luo served as the senior manager of the Elderly Care Business Department, the executive secretary of the Board Office and deputy general manager of the Internal Control and Compliance Department of Zhongrong Life Insurance from September 2021 to April 2022; and as the secretary to the chairman of Zhongtian Financial Group Company Limited from February 2020 to September 2021. Mr. Luo graduated from University of Northampton with a Bachelor of Arts degree in Business & Management in 2020.

Zhang Shengman, has been an Independent Non-Executive Director of the Company since December 2006. As of 31?December 2024, Mr. Zhang has also been a non-executive director of Seazen Group Limited (listed on the Hong Kong Stock Exchange with stock code 01030) and an independent non-executive director of China Lilang Limited (listed on the Hong Kong Stock Exchange with stock code 01234) and Green Economy Development Limited (listed on the Hong Kong Stock Exchange with stock code 01315). Mr. Zhang worked in the PRC Ministry of Finance as a deputy director and vice secretary from 1987 to 1992. From 1993 to 2005, Mr. Zhang served as an executive director for China, vice president and chief secretary, senior vice director, managing director and chairman of the operations committee, the sanctions committee and the corporate committee on fraud and corruption policy of the World Bank. Mr. Zhang joined Citigroup Inc. (listed on the NYSE with stock code C) in February 2006, and up to May 2016 once served as the chairman of the Public Sector Group, president and chairman of Asia Pacific. Mr. Zhang received a bachelor’s degree in English literature in 1978 from Fudan University and a master’s degree in public administration in 1986 from University of the District of Columbia. Mr. Zhang completed the Harvard Advanced Management Program in 1997.

Zhang Huaqiao, has been an Independent Non-Executive Director of the Company since March 2012. As of 31?December 2024, Mr. Zhang has been an independent non-executive director of Zhong An Group Limited (listed on the Hong Kong Stock Exchange with stock code 00672), Logan Group Company Limited (listed on the Hong Kong Stock Exchange with stock code 03380), Luye Pharma Group Ltd. (listed on the Hong Kong Stock Exchange with stock code 02186) and Radiance Holdings (Group) Company Limited (listed on the Hong Kong Stock Exchange with stock code 09993). Mr. Zhang was an independent non-executive director of Haitong International Securities Group Limited (delisted from the Hong Kong Stock Exchange in January 2024). From July 1986 to January 1989, Mr. Zhang was employed at the People’s Bank of China and from June 1999 to April 2006, Mr. Zhang worked at the Equities Department of UBS AG, Hong Kong Branch at which he first served as the head of China research team and later became co-head of China research team. Mr. Zhang was the chief operating officer from March 2006 to September 2008 and an executive director from May 2006 to September 2008 of Shenzhen Investment Limited (listed on the Hong Kong Stock Exchange with stock code 00604). From September 2008 to June 2011, he was the deputy head of China Investment Banking at UBS Securities Asia Limited. Mr. Zhang was also a non- executive director of Boer Power Holdings Limited (listed on the Hong Kong Stock Exchange with stock code 01685), an independent non-executive director of China Huirong Financial Holdings Limited (listed on the Hong Kong Stock Exchange with stock code 01290), and China Rapid Finance Limited (listed on the NYSE with stock code XRF), and a non-executive director, executive director and chairman of China Smartpay Group Holdings Limited (listed on the Hong Kong Stock Exchange with stock code 08325). Mr. Zhang graduated from the Graduate School of the People’s Bank of China with a master’s degree in economics in 1986, and from the Australian National University with a master’s degree in economics in 1991.

David T. Zhang, has been an Independent Non-Executive Director of the Company since June 2012. Mr. Zhang has also been a senior corporate partner in the Hong Kong office of Kirkland & Ellis International LLP, a leading international law firm, non-executive director of Noah Holdings Private Wealth and Asset Management Limited and a director of WeRide Inc. (listed on NASDAQ with stock code WRD). Admitted to the practice of law in the State of New York, USA and based in Hong Kong, Mr. Zhang specializes in securities offerings and M&A transactions. He has extensive experience representing Chinese issuers and leading investment banks in US initial public offerings, Hong Kong initial public offerings and other Rule 144A and Regulation S offerings of equity, debt and convertible securities. Mr. Zhang has represented a number of leading private equity funds, multinational corporations and sovereign wealth funds in connection with their investments and M&A transactions in the Greater China region and Southeast Asia. In addition, Mr. Zhang has successfully guided China-based companies listed in the United States and Hong Kong through complex mission-critical moments, counselling leaders and boards of directors on high-stakes matters at the intersection of litigation, regulatory enforcement, reputation and public policy. Mr. Zhang has been rated as a top capital markets attorney by Chambers Global, Legal 500 Asia Pacific, IFLR1000 and Chambers Asia Pacific. Prior to joining Kirkland & Ellis International LLP in August 2011, Mr. Zhang was a partner of Latham & Watkins LLP, a leading international law firm, for eight years. Mr. Zhang graduated from Beijing Foreign Studies University in 1981 and received his J.D. degree from Tulane University Law School in 1991.

Lee Kai-Fu, has been an Independent Non-Executive Director of the Company since March 2017. As of 31?December 2024, Dr. Lee has also been the director of Sinovation (HK) Investment Management Co. Limited, the managing partner of the Beijing Sinovation Ventures Private Equity Fund Management Limited, the director of Sinovation Ventures (Beijing) Enterprise Management Co., Ltd., and the chairman and non-executive director of Qingdao Ainnovation Technology Group Co., Ltd (listed on the Hong Kong Stock Exchange with stock code 02121). Dr. Lee has also serves as the one of the principals of several funds managed by Sinovation Ventures and as a director or board chairman for various companies in the internet, artificial intelligence and other industries. From 1988 to 1990, Dr. Lee worked at Carnegie Mellon University, where he served as an assistant professor; between July 1990 and April 1996, Dr. Lee worked at Apple Inc. (listed on NASDAQ with stock code AAPL), serving as a vice president from December 1995; from July 1998 to July 2005, Dr. Lee was the vice president of Microsoft Corporation (listed on NASDAQ with stock code MSFT); from July 2005 to September 2009, Dr. Lee was the president of Google China of Google Inc. (listed on NASDAQ with stock code GOOGL), and he was responsible for launching the Google China R&D Centre. Dr. Lee was also an independent director of LightInTheBox Holding Co., Ltd. (listed on the NYSE with stock code LITB), an independent non-executive director of Shangri-La Asia Limited (listed on the Hong Kong Stock Exchange with stock code 00069) and Hon Hai Precision Industry Co., Ltd. (listed on the Taiwan Stock Exchange with stock code 2317) and a non- executive director of Meitu, Inc. (listed on the Hong Kong Stock Exchange with stock code 01357). Dr. Lee received his bachelor’s degree and Ph.D. in Computer Science from Columbia University in 1983 and Carnegie Mellon University in 1988, respectively, as well as Honorary Doctorate Degrees from both the City University of Hong Kong and Carnegie Mellon University in 2010 and 2015, respectively.?

Tsang King Suen Katherine, has been an Independent Non-Executive Director of the Company since December 2020. Ms. Tsang is the founder of Max Giant Capital. As of 31?December 2024, Ms. Tsang has also been an independent non-executive director of Budweiser Brewing Company APAC Limited (listed on the Hong Kong Stock Exchange with stock code 01876), Fidelity Emerging Markets Limited (listed on the London Stock Exchange with stock code FEML) and China CITIC Bank International Limited. Ms. Tsang was an executive director and chief executive officer of HK Acquisition Corporation (listed on the Hong Kong Stock Exchange with stock code 07841) from February 2022 to October 2024. Ms. Tsang was an independent non-executive director of Baoshan Iron & Steel Co., Ltd. (listed on the SSE with stock code 600019) from May 2006 to April 2012, the chairperson of Greater China of Standard Chartered Bank from August 2009 to August 2014, an independent non-executive director of Gap Inc. (listed on the NYSE with stock code GAP) from August 2010 to May 2018. As of 31?December 2024, Ms. Tsang has been a member of the Advisory Council for China of the City of London, an honorary board member of Shanghai Jiao Tong University. Ms. Tsang was a member of the World Economic Forum’s Global Agenda Council on China from 2009 to 2012 and a member of Sotheby’s Asia Advisory Board from November 2011 to October 2014. Ms. Tsang graduated from University of Alberta, Canada with a bachelor’s degree in Commerce in 1978.